BSE filing, NSE: ALSL. Summary written from the filing by ALFA Finder's alert engine.
Alacrity Securities Ltd: key numbers
- Share price
- ₹41.79
- Market cap
- ₹195.0 Cr
- Revenue (annual)
- ₹410.7 Cr
- Net profit (annual)
- ₹6.21 Cr
- P/E (TTM)
- 20.0×Sector 19.1×
- Promoter holding
- 54.34%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alacrity Securities Ltd
All →Alacrity Securities Board Meeting Date
Alacrity Securities schedules a November 2, 2026 board meeting to consider unaudited standalone results. The meeting is proposed only; results are not yet approved.
Alacrity Securities Other Announcement
Alacrity Securities Ltd has filed its quarterly shareholding pattern as mandated by Regulation 31(1)(b) of the SEBI (LODR) Regulations for the quarter ending September 30, 2026.
Alacrity Securities Annual General Meeting
Alacrity Securities Ltd held its 32nd Annual General Meeting on September 30, 2026. The meeting covered routine resolutions including financial statements, director reappointment, and dividend declaration.
Alacrity Securities Price Movement Clarification
Alacrity Securities Ltd clarified that its recent share price movement is purely market-driven, confirming no pending undisclosed price-sensitive information exists.
Alacrity Securities Promoter Selling (Off-Market)
Promoter Hiten Ramniklal Mehta disposed of 8,11,478 shares of Alacrity Securities Limited through an off-market gift transfer. This reduces his stake in the target company.
- Promoter stake change
- -0.17%
Alacrity Securities Promoter Buying (Off-Market)
Hemanshu Ramniklal Mehta acquired 12,17,217 shares of Alacrity Securities Limited via an off-market gift. The promoter's stake increased by 2.61%.
- Promoter stake change
- +2.61%
Other regulatory approval announcements
All →Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
RNFI Services Regulatory Approval
RNFI received RBI no-objection to acquire control of Smart Payment Solutions Private Limited. Remaining tranches may proceed, but no transaction value is disclosed.
Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.